- Home
- SNX vs LEGN Comparison
SNX vs LEGN Comparison
Compare SNX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- LEGN
- Stock Information
- Founded
- SNX 1980
- LEGN 2014
- Country
- SNX United States
- LEGN United States
- Employees
- SNX N/A
- LEGN N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- LEGN Health Care
- Exchange
- SNX Nasdaq
- LEGN Nasdaq
- Market Cap
- SNX 9.5B
- LEGN 9.1B
- IPO Year
- SNX 2003
- LEGN 2020
- Fundamental
- Price
- SNX $116.02
- LEGN $40.14
- Analyst Decision
- SNX Buy
- LEGN Strong Buy
- Analyst Count
- SNX 8
- LEGN 13
- Target Price
- SNX $134.75
- LEGN $81.46
- AVG Volume (30 Days)
- SNX 536.6K
- LEGN 1.5M
- Earning Date
- SNX 01-07-2025
- LEGN 11-12-2024
- Dividend Yield
- SNX 1.38%
- LEGN N/A
- EPS Growth
- SNX 10.98
- LEGN N/A
- EPS
- SNX 7.74
- LEGN N/A
- Revenue
- SNX $57,015,179,000.00
- LEGN $520,183,000.00
- Revenue This Year
- SNX $1.61
- LEGN $110.04
- Revenue Next Year
- SNX $5.74
- LEGN $77.16
- P/E Ratio
- SNX $14.96
- LEGN N/A
- Revenue Growth
- SNX N/A
- LEGN 122.96
- 52 Week Low
- SNX $96.93
- LEGN $37.40
- 52 Week High
- SNX $133.85
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- SNX 43.83
- LEGN 41.41
- Support Level
- SNX $114.41
- LEGN $36.92
- Resistance Level
- SNX $126.56
- LEGN $41.87
- Average True Range (ATR)
- SNX 2.57
- LEGN 2.32
- MACD
- SNX -0.70
- LEGN -0.09
- Stochastic Oscillator
- SNX 13.25
- LEGN 29.62
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and datacenter infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include, the Americas, Europe, and APJ.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.